These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29959141)

  • 1. Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.
    Kannan P; Kretzschmar WW; Winter H; Warren D; Bates R; Allen PD; Syed N; Irving B; Papiez BW; Kaeppler J; Markelc B; Kinchesh P; Gilchrist S; Smart S; Schnabel JA; Maughan T; Harris AL; Muschel RJ; Partridge M; Sharma RA; Kersemans V
    Clin Cancer Res; 2018 Oct; 24(19):4694-4704. PubMed ID: 29959141
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density.
    Chen J; Chen C; Xia C; Huang Z; Zuo P; Stemmer A; Song B
    Abdom Radiol (NY); 2018 Jun; 43(6):1393-1403. PubMed ID: 28939963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
    Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
    Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
    Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F
    J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
    Zhang CC; Yan Z; Giddabasappa A; Lappin PB; Painter CL; Zhang Q; Li G; Goodman J; Simmons B; Pascual B; Lee J; Levkoff T; Nichols T; Xie Z
    Cancer Med; 2014 Jun; 3(3):462-71. PubMed ID: 24573979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
    Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
    Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.
    Fasol U; Frost A; Büchert M; Arends J; Fiedler U; Scharr D; Scheuenpflug J; Mross K
    Ann Oncol; 2012 Apr; 23(4):1030-6. PubMed ID: 21693769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
    Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
    Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
    Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
    Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
    Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
    Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.
    Zhang W; Chen HJ; Wang ZJ; Huang W; Zhang LJ
    Eur Radiol; 2017 May; 27(5):2086-2094. PubMed ID: 27488851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
    Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
    Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
    J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
    Consolino L; Longo DL; Sciortino M; Dastrù W; Cabodi S; Giovenzana GB; Aime S
    Gastric Cancer; 2017 Jul; 20(4):629-639. PubMed ID: 27995483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
    Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
    Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results.
    Yeo DM; Oh SN; Jung CK; Lee MA; Oh ST; Rha SE; Jung SE; Byun JY; Gall P; Son Y
    J Magn Reson Imaging; 2015 Feb; 41(2):474-80. PubMed ID: 24375840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.
    Fleten KG; Bakke KM; Mælandsmo GM; Abildgaard A; Redalen KR; Flatmark K
    Clin Exp Metastasis; 2017 Jan; 34(1):51-62. PubMed ID: 27812769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.